Testing Glypican-3 to predict outcomes in liver cancer immunotherapy
Part of Cancer, Digestive system clinical trials.
This study looks at a blood/tissue marker called Glypican-3 to see who is more likely to do well when treated with immunotherapy for liver cancer. It may help doctors predict outcomes and tailor future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and under 90 years old.
- You have liver cancer (HCC) arising from long-term liver disease or cirrhosis.
- Your treatment plan includes the combination of atezolizumab plus bevacizumab for liver cancer.
- You can understand and communicate in French and agree to join the study.
- You should not have immune system problems or take medicines that strongly suppress immunity.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial aims to discover new immune system targets on liver cancer cells and other tumors to develop better immunotherapies. Researchers will analyze tumor samples to find these targets, which could lead to more effective treatments.
This trial tests if combining two immunotherapy drugs (atezolizumab and bevacizumab) with a brain-health medicine (memantine) can help people with advanced liver cancer that isn't treatable with surgery. It aims to see if this triple therapy works better than standard options.
This trial studies how liver cancer changes during immunotherapy and looks for biological markers that may predict treatment response. It helps doctors understand why some patients benefit more from treatment.
This study looks at how well immune-checkpoint therapy (a PD-1 or PD-L1 immunotherapy) works for advanced liver cancer, using “liquid biopsy” blood testing to guide or monitor care. It may help your team better track your cancer and response without needing repeated tissue biopsies.
This study looks at a genetic test that may predict how well liver cancer patients respond to combination treatment with targeted therapy and immunotherapy. If eligible, your stored tumor tissue will be analyzed to see if a specific gene pattern can tell whether this treatment works for you.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.